Document is current
Any future updates will be listed below
-
Authors
Chiang, Chi-Lu
Ho, Hsiang-Ling
Yeh, Yi-Chen
Lee, Cheng-Chia
Huang, Hsu-Ching
Shen, Chia-I
Luo, Yung-Hung
Chen, Yuh-Min
Chiu, Chao-Hua
Chou, Teh-Ying
-
Funding
Funding for this research was provided by:
Taipei Veterans General Hospital (V110B-008)
- License Information
-
More Information
Article History
Received: 2 September 2022
Accepted: 5 October 2022
First Online: 1 November 2022
Declarations
:
: CLC had received honoraria from AstraZeneca, Boehringer Ingelheim, Pfizer, and Roche. YHL had received honoraria from AstraZeneca, Boehringer Ingelheim, and Pfizer. YMC had received honoraria from Boehringer Ingelheim, Eli Lilly, Roche/Genentech/Chugai, MSD, Pfizer, Novartis, BMS, Ono Pharmaceutical, AstraZeneca, and Takeda Oncology; and served as advisor for Boehringer Ingelheim, Eli Lilly, Roche/Chugai, MSD, AstraZeneca, and Takeda Oncology. CHC had received honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche, and Takeda. Others declare no conflict of interest that might be relevant to the contents of this manuscript.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Taipei Veterans General Hospital, Taiwan.
